Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Current Leases (2022 - 2025)

Dianthus Therapeutics (DNTH) has 4 years of Current Leases data on record, last reported at $217000.0 in Q3 2025.

  • For Q3 2025, Current Leases fell 30.23% year-over-year to $217000.0; the TTM value through Sep 2025 reached $217000.0, down 30.23%, while the annual FY2024 figure was $320000.0, 23.26% down from the prior year.
  • Current Leases reached $217000.0 in Q3 2025 per DNTH's latest filing, up from $211000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $3.6 million in Q3 2022 and bottomed at $211000.0 in Q2 2025.
  • Average Current Leases over 4 years is $1.0 million, with a median of $377000.0 recorded in 2024.
  • The widest YoY moves for Current Leases: up 19.14% in 2023, down 88.59% in 2023.
  • A 4-year view of Current Leases shows it stood at $350000.0 in 2022, then grew by 19.14% to $417000.0 in 2023, then fell by 23.26% to $320000.0 in 2024, then plummeted by 32.19% to $217000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $217000.0 in Q3 2025, $211000.0 in Q2 2025, and $226000.0 in Q1 2025.